Skip to main content
SpringerLink
Log in

Extraintestinal Manifestations of Inflammatory Bowel Disease

  • Chapter
  • First Online:
Periodic and Non-Periodic Fevers

Part of the book series: Rare Diseases of the Immune System ((RDIS))

Abstract

Inflammatory bowel diseases (IBDs) are complex inflammatory disorders of the gastrointestinal tract which could involve multiple organ systems and present with various extraintestinal manifestations. Almost every organ system may be affected in IBD including the musculoskeletal system, skin, eyes, liver, lungs, kidneys, immune system, hematologic system, and cardiovascular system. Certain extraintestinal manifestations are frequently related to the activity of the IBD (peripheral arthritis, oral ulcers, erythema nodosum, episcleritis), while others develop independently of the intestinal inflammation (axial arthropathies, hepatobiliary disorders). The etiopathogenesis of IBD is complex and includes interaction between environmental factors and immune system in genetically susceptible individuals. Autoinflammation is becoming increasingly recognized as an important component in the pathogenesis of IBD, especially Crohn’s disease. Genetic loci specifically associated with Crohn’s disease consistently implicate involvement of innate immunity (CARD15/NOD2, IRGM, IL23R, LRRK2, and ATG16L1) and de-regulated adaptive immune responses, namely, the interleukin-23 and T helper 17 cell pathways. This chapter provides comprehensive review of various extraintestinal manifestations associated with IBD with specific focus on autoinflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26:265–73.

    Article  PubMed  Google Scholar 

  2. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110.

    Article  PubMed  Google Scholar 

  3. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, navarinis A, Rogler G. Extraintestinal manifestation of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1982–92.

    Article  PubMed  Google Scholar 

  4. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401–12.

    Article  CAS  Google Scholar 

  5. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227–36.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Heyman MB. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:63–8.

    Article  PubMed  Google Scholar 

  7. Jose FA, Heyman MB. Extraintestinal manifestation of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2008;46:124–33.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin N Am. 2002;31:307–27.

    Article  Google Scholar 

  9. Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn’s disease. F1000Prime Rep. 2015;7:44. https://doi.org/10.12703/P7-44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith G, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867–74.

    Article  CAS  PubMed  Google Scholar 

  13. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–4.

    Article  CAS  PubMed  Google Scholar 

  14. Ogura Y, Lala S, Xin W, Smith E, Dowds TA, Chen FF, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis. Gut. 2003;52:1591–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jiang W, Wang X, Zeng B, Liu L, Tardivel A, Wei H, et al. Recognition of gut microbiota by NOD2 is essential for the homeostasis of intestinal intraepithelial lymphocytes. J Exp Med. 2013;210:2465–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bevins CL, Stange EF, Wehkamp J. Decreased Paneth cell defensin expression in ileal Crohn’s disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut. 2009;58:882–3.

    CAS  PubMed  Google Scholar 

  17. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010;16:90–7.

    Article  CAS  PubMed  Google Scholar 

  18. Lapaquette P, Bringer M, Darfeuille-Michaud A. Defects in autophagy favour adherent-invasive Escherichia coli persistence within macrophages leading to increased pro-inflammatory response. Cell Microbiol. 2012;14:791–807.

    Article  CAS  PubMed  Google Scholar 

  19. Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985;80:615–20.

    CAS  PubMed  Google Scholar 

  20. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–6.

    Article  CAS  PubMed  Google Scholar 

  21. Uehara A, Yang S, Fujimoto Y, Fukase K, Kusumoto S, Shibata K, et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol. 2005;7:53–61.

    Article  CAS  PubMed  Google Scholar 

  22. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W. Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity. 2006;25:473–85.

    Article  CAS  PubMed  Google Scholar 

  23. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19–20.

    Article  CAS  PubMed  Google Scholar 

  24. Ferrero-Miliani L, Nielsen OH, Andersen PS. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1 generation. Clin Exp Immunol. 2007;147(2):227–35.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell. 2014;157:65–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ke P, Shao BZ, Xu ZQ, Chen XW, Liu C. Intestinal autophagy and its pharmacological control in inflammatory bowel disease. Front Immunol. 2016;7:695. https://doi.org/10.3389/fimmu.2016.00695.

    Article  CAS  PubMed  Google Scholar 

  28. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–22.

    Article  CAS  PubMed  Google Scholar 

  29. Smale S, Natt RS, Orchard TR, et al. Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum. 2001;44:2728–36.

    Article  CAS  PubMed  Google Scholar 

  30. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83:703–9.

    CAS  PubMed  Google Scholar 

  31. Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9(10):2300–7.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Rankin GB, Watts HD, Melnyk CS, Kelley ML Jr. National cooperative Crohn’s disease study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77(4 Pt 2):914–20.

    Article  CAS  PubMed  Google Scholar 

  33. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  34. Biancone L, Mandal A, Yang H, et al. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology. 1995;109:3–12.

    Article  CAS  PubMed  Google Scholar 

  35. Jacques P, Elewaut D. Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol. 2008;1:364–71.

    Article  CAS  PubMed  Google Scholar 

  36. Das KM, Sakamaki S, Vecchi M, et al. The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: cellular localization of the antigen by using the monoclonal antibody. J Immunol. 1987;139:77–84.

    CAS  PubMed  Google Scholar 

  37. Geng X, Biancone L, Dai HH, et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912–22.

    Article  CAS  PubMed  Google Scholar 

  38. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology. 1994;107:103–8.

    Article  CAS  PubMed  Google Scholar 

  39. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359–64.

    Article  CAS  PubMed  Google Scholar 

  40. Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;166:4650–7.

    Article  CAS  PubMed  Google Scholar 

  41. May E, Märker-Hermann E, Wittig BM, et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology. 2000;119:1745–55.

    Article  CAS  PubMed  Google Scholar 

  42. Demetter P, De Vos M, Van Huysse JA, et al. Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis. 2005;64:321–4.

    Article  CAS  PubMed  Google Scholar 

  43. Baeten D, Demetter P, Cuvelier CA, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol. 2002;196:343–50.

    Article  CAS  PubMed  Google Scholar 

  44. Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte subtype specific adhesion. J Clin Invest. 1997;99:2165–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Armaka M, Apostolaki M, Jacques P, et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008;205:331–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLAB27-associated human disorders. Cell. 1990;63(5):1099–112.

    Article  CAS  PubMed  Google Scholar 

  47. Diaz-Peromingo JA, Garcia-Suarez F, Sanchez-Leira J, Saborido Frojan J. Sweet’s syndrome in a patient with acute ulcerative colitis: presentation of a case and review of the literature. Yale J Biol Med. 2001;74:165–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lanna CC, Ferrari ML, Rocha SL, Nascimento E, de Carvalho MA, da Cunha AS. A cross-sectional study of 130 Brazilian patients with Crohn’s disease and ulcerative colitis: analysis of articular and ophthalmologic manifestations. Clin Rheumatol. 2008;27(4):503–9.

    Article  PubMed  Google Scholar 

  50. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn’s disease. Gastroenterology. 1979;77(4 Pt 2):898–906.

    Article  CAS  PubMed  Google Scholar 

  51. de Vlam K, Mielants H, Cuvelier C, de Keyser F, Veys EM, de Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;27(12):2860–5.

    PubMed  Google Scholar 

  52. Palm O, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford). 2001;40(11):1256–61.

    Article  CAS  Google Scholar 

  53. Brakenhoff LKPM, van der Heijde DM, Hommes DW, Huizinga TWJ, Fidder HH. The joint–gut axis in inflammatory bowel diseases. J Crohns Colitis. 2010;4(3):257–68.

    Article  PubMed  Google Scholar 

  54. Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? AmJ Gastroenterol. 2009;104:1298–313; quiz 1314.

    Article  CAS  Google Scholar 

  55. Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis. 2008;2(1):63–92.

    Article  PubMed  Google Scholar 

  56. Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbationof inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009;65(10):963–70.

    Article  PubMed  Google Scholar 

  57. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000;356:1821–2.

    Article  PubMed  Google Scholar 

  58. Ellman MH, Hanauer S, Sitrin M, et al. Crohn’s disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol. 2001;7:67–71.

    Article  CAS  PubMed  Google Scholar 

  59. Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006;65:423–32.

    Article  CAS  PubMed  Google Scholar 

  60. Vavricka SR, Scharl M, Gubler M, et al. Which extraintestinal manifestations of IBD respond to biologics? Curr Drug Targets. 2014;15:1064–73.

    Article  CAS  PubMed  Google Scholar 

  61. Ko JS, Uberti G, Napekoski K, Patil DT, Billings SD. Cutaneous manifestations in inflammatory bowel disease: a single institutional study of non-neoplastic biopsies over 13 yeras. J Cutan Pathol. 2016;43:946–55.

    Article  PubMed  Google Scholar 

  62. Tavarela Veloso F. Skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(Suppl 4):50–3.

    Article  PubMed  Google Scholar 

  63. Tavarela Veloso F, Carvalho S, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29–34.

    Article  Google Scholar 

  64. Georgiou G, Pasmatzi E, Monastirli A, Tsambaos D. Cutaneous manifestations of inflammatory bowel disease. Hosp Chron. 2006;1:158–68.

    Google Scholar 

  65. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis and management. Ann Med. 2010;42:97–114.

    Article  PubMed  Google Scholar 

  66. Ploysangam T, Heubi JE, Eisen D, Balistreri WF, Lucky AW. Cutaneous Crohn’s disease in children. J Am Acad Dermatol. 1997;36:697–704.

    Article  CAS  PubMed  Google Scholar 

  67. Lestre S, Ramos J, Joao A, Serrao V. Cutaneous Crohn’s disease presenting as genital warts: successful treatment with adalimumab. Eur J Dermatol. 2010;20:504–5.

    PubMed  Google Scholar 

  68. Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:13.

    PubMed  PubMed Central  Google Scholar 

  69. Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore). 2008;87:281.

    Article  Google Scholar 

  70. Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, et al. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol. 2007;21:408–10.

    Article  CAS  PubMed  Google Scholar 

  71. Fleisher M, Rubin S, Levine A, et al. Infliximab in the treatment of steroid refractory erythema nodosum of IBD. Gastroenterology. 2002;122(Suppl. 1):A618 (Abstract).

    Google Scholar 

  72. Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr. 2003;37:150–4.

    Article  CAS  PubMed  Google Scholar 

  73. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine. 2000;79:37–46.

    Article  CAS  PubMed  Google Scholar 

  74. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002;123:714.

    Article  PubMed  Google Scholar 

  75. Orchard T. Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep. 2003;5:512–7.

    Article  PubMed  Google Scholar 

  76. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581–5.

    Article  CAS  PubMed  Google Scholar 

  77. Trost L, McDonnell J. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81(959):580–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Cohen PR, Kurzrock R. Sweet’s syndrome revisited: a review of disease concepts. Int J Dermatol. 2003;42:761–78.

    Article  PubMed  Google Scholar 

  79. Guhl G, Garcia-Diez A. Subcutaneous sweet syndrome. Dermatol Clin. 2008;26:541–51.

    Article  PubMed  Google Scholar 

  80. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40(Suppl. 2):S253–9.

    Article  PubMed  Google Scholar 

  81. Vij A, Modi GM, Suwattee P, Cockerell CJ, Hsu S. Chronic, recurrent neutrophilic dermatosis: a case report. Dermatology. 2010;16:1.

    Google Scholar 

  82. Ali M, Duerksen DR. Ulcerative colitis and Sweet’s syndrome: a case report and review of the literature. Can J Gastroenterol. 2008;22:296–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Su WP, Liu HN. Diagnostic criteria for Sweet’s syndrome. Cutis. 1986;37(3):167–74.

    Google Scholar 

  84. Cohen PR. Sweet’s syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.

    Google Scholar 

  85. Nofal A, Abdelmaksoud A, Amer H, et al. Sweet’s syndrome: diagnsotic criteria revisited. J Dtsch Dermatol Ges. 2017;15:1081–8.

    PubMed  Google Scholar 

  86. Cohen PR, Kurzrock R. Sweet’s syndrome: a review of current treatment options. Am J Clin Dermatol. 2001;3:117–31.

    Article  CAS  Google Scholar 

  87. Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol. 2009;10:301–12.

    Article  PubMed  Google Scholar 

  88. Ashok D, Kiely P. Bowel associated dermatosis–arthritis syndrome: a case report. J Med Case Rep. 2007;1:81.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Patton T, Jukic D, Juhas E. A typical histopathology in bowel associated dermatosis – arthritis syndrome: a case report. Dermatol Online J. 2009;15:3.

    PubMed  Google Scholar 

  90. Truchuelo MT, Alcántara J, Vano-Galván S, et al. Bowel associated dermatosis-arthritis syndrome: another cutaneous manifestation of inflammatory intestinal disease. Int J Dermatol. 2013;52:1596–8.

    Article  PubMed  Google Scholar 

  91. Nischal KC, Khopkar U. An approach to the diagnosis of neutrophilic dermatoses: a histopathological perspective. Indian J Dermatol Venereol Leprol. 2007;73:222–30.

    Article  CAS  PubMed  Google Scholar 

  92. Mackel SE, Jordon RE. Leukocytoclastic vasculitis. A cutaneous expression of immune complex disease. Arch Dermatol. 1982;118:296–301.

    Article  CAS  PubMed  Google Scholar 

  93. Iannone F, Scioscia C, Musio A, Piscitelli D, Lapadula G. Leukocytoclastic vasculitis as onset symptom of ulcerative colitis. Ann Rheum Dis. 2003;62:785–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Akbulut S, Ozaslan E, Topal F, Albayrak L, Kayhan B, Efe C. Ulcerative colitis presenting as leukocytoclastic vasculitis of skin. World J Gastroenterol. 2008;14:2448–50.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Tsiamoulos Z, Karamanolis G, Polymeros D, Triantafyllou K, Oikonomopoulos T. Leukocytoclastic vasculitis as an onset symptom of Crohn’s disease. Case Rep Gastroenterol. 2008;2:410–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin and biliary epithelium detected by a monoclonal antibody. Gastroenterology. 1990;98:464.

    Article  CAS  PubMed  Google Scholar 

  97. Lourenço S, Hussein T, Bologna S, Sipahi A, Nico M. Oral manifestations of inflammatory bowel disease: a review based on the observation of six cases. J Eur Acad Dermatol Venereol. 2010;24(2):204–7.

    Article  PubMed  CAS  Google Scholar 

  98. Pittock S, Drumm B, Fleming P, McDermott M, Imrie C, Flint S, et al. The oral cavity in Crohn’s disease. J Pediatr. 2001;138(5):767–71.

    Article  CAS  PubMed  Google Scholar 

  99. Michailidou E, Arvanitidou S, Lombardi T, Kolokotronis A, Antoniades D, Samson J. Oral lesions leading to the diagnosis of Crohn disease: report on 5 patients. Quintessence Int. 2009;40(7):581–8.

    PubMed  Google Scholar 

  100. Zbar AP, Ben-Horin S, Beer-Gabel M, Eliakim R. Oral Crohn’s disease: is it a separable disease from orofacial granulomatosis? A review. J Crohns Colitis. 2012;6(2):135–42.

    Article  PubMed  Google Scholar 

  101. Harty S, Fleming P, Rowland M, Crushell E, McDermott M, Drumm B, et al. A prospective study of the oral manifestations of Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3(9):886–91.

    Article  PubMed  Google Scholar 

  102. Halme L, Meurman JH, Laine P, von Smitten K, Syrjänen S, Lindqvist C, et al. Oral findings in patients with active or inactive Crohn’s disease. Oral Surg Oral Med Oral Pathol Oral Radiol. 1993;76(2):175–81.

    Article  CAS  Google Scholar 

  103. Williams A, Wray D, Ferguson A. The clinical entity of orofacial Crohn’s disease. Q J Med. 1991;79(2):451–8.

    CAS  PubMed  Google Scholar 

  104. Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;72(18):2333–49.

    Article  CAS  PubMed  Google Scholar 

  105. McCullough MJ, Abdel-Hafeth S, Scully C. Recurrent aphthous stomatitis revisited; clinical features, associations, and new association with infant feeding practices? J Oral Pathol Med. 2007;36(10):615–20.

    Article  PubMed  Google Scholar 

  106. Liu C, Zhou Z, Liu G, Wang Q, Chen J, Wang L, et al. Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am J Med. 2012;125(3):292–301.

    Article  CAS  PubMed  Google Scholar 

  107. McBride DR. Management of aphthous ulcers. Am Fam Physician. 2000;62(1):149–54, 60.

    CAS  PubMed  Google Scholar 

  108. McCarthy FP. Pyostomatitis vegetans: report of three cases. Arch Dermatol Syphilol. 1949;60(5_PART_I):750–64.

    Article  CAS  Google Scholar 

  109. Field E, Allan R. Oral ulceration–aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment Pharmacol Ther. 2003;18(10):949–62.

    Article  CAS  PubMed  Google Scholar 

  110. Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterol. 2013;19(46):8571.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Daley TD, Armstrong JE. Oral manifestations of gastrointestinal diseases. Can J Gastroenterol Hepatol. 2007;21(4):241–4.

    Google Scholar 

  112. Mijandrušić-Sinčić B, Licul V, Gorup L, Brnčić N, Glažar I, Lučin K. Pyostomatitis vegetans associated with inflammatory bowel disease–report of two cases. Coll Antropol. 2010;34(2):279–82.

    PubMed  Google Scholar 

  113. Matias FA, Rosa DJ, Carvalho MT, Castañon MC. Pyodermatitis-pyostomatitis vegetans: case report and review of medical literature. An Bras Dermatol. 2011;86(4):137–40.

    Article  Google Scholar 

  114. Jurge S, Hegarty AM, Hodgson T. Orofacial manifestations of gastrointestinal disorders. Br J Hosp Med. 2014;75(9):497–501.

    Article  Google Scholar 

  115. Femiano F, Lanza A, Buonaiuto C, Perillo L, Dell’Ermo A, Cirillo N. Pyostomatitis vegetans: a review of the literature. Med Oral Patol Oral Cir Bucal. 2009;14(3):E114–7.

    PubMed  Google Scholar 

  116. Ficarra G, Cicchi P, Amorosi A, Piluso S. Oral Crohn’s disease and pyostomatitis vegetans. An unusual association. Oral Surg Oral Med Oral Pathol. 1993;75(2):220–4.

    Article  CAS  PubMed  Google Scholar 

  117. Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: Part II. J Am Acad Dermatol. 2013;68(2):211.e1–211.e33.

    Article  Google Scholar 

  118. Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohns Colitis. 2016;10(4):429–36.

    Article  PubMed  Google Scholar 

  119. Cury DB, Moss AC. Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;16(8):1393–6.

    Article  Google Scholar 

  120. Felekis T, Katsanos K, Kitsanou M, Trakos N, Theopistos V, Christodoulou D, et al. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis. 2008;15(1):29–34.

    Article  Google Scholar 

  121. Ottaviano G, Salvatore S, Salvatoni A, Martelossi S, Ventura A, Naviglio S. Ocular manifestations of pediatric inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2018;12(7):870–9.

    Article  PubMed  Google Scholar 

  122. Karlinger K, Györke T, Makö E, Mester Á, Tarján Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol. 2000;35(3):154–67.

    Article  CAS  PubMed  Google Scholar 

  123. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease (new insights into autoimmune pathogenesis). Digest Dis Sci. 1999;44(1):1–13.

    Article  CAS  PubMed  Google Scholar 

  124. Santeford A, Wiley LA, Park S, Bamba S, Nakamura R, Gdoura A, et al. Impaired autophagy in macrophages promotes inflammatory eye disease. Autophagy. 2016;12(10):1876–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7(4):235.

    Google Scholar 

  126. Generali E, Cantarini L, Selmi C. Ocular involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol. 2015;49(3):263–70.

    Article  CAS  PubMed  Google Scholar 

  127. Mady R, Grover W, Butrus S. Ocular complications of inflammatory bowel disease. ScientificWorldJournal. 2015;2015:438402.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–54.

    Article  PubMed  Google Scholar 

  129. Evans PE, Pardi DS. Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. Medscape Gen Med. 2007;9(1):55.

    Article  CAS  Google Scholar 

  130. Watson PG, Young RD. Scleral structure, organisation and disease. A review. Exp Eye Res. 2004;78(3):609–23.

    Article  CAS  PubMed  Google Scholar 

  131. Williams H, Walker D, Orchard TR. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2008;10(6):597–605.

    Article  PubMed  Google Scholar 

  132. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(2):135–9.

    Article  PubMed  Google Scholar 

  133. Group SoUNW. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–16.

    Article  Google Scholar 

  134. Bodaghi B, Quoc EB, Wechsler B, Tran T, Cassoux N, Huong DLT, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis. 2005;64(6):962–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Troncoso LL, Biancardi AL, de Moraes HV Jr, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: a review. World J Gastroenterol. 2017;23(32):5836–48.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Durno CA, Ehrlich R, Taylor R, Buncic JR, Hughes P, Griffiths AM. Keeping an eye on Crohn’s disease: orbital myositis as the presenting symptom. Can J Gastroenterol. 1997;11(6):497–500.

    Article  CAS  PubMed  Google Scholar 

  137. Pusateri AJ, Kim SC, Dotson JL, et al. Incidence, pattern, and etiology of elevated liver enzymes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2015;60:592–7.

    Article  CAS  PubMed  Google Scholar 

  138. Valentino PL, Feldman BM, Walters TD, et al. Abnormal liver biochemistry is common in pediatric inflammatory bowel disease: prevalence and associations. Inflamm Bowel Dis. 2015;21:2848–56.

    Article  PubMed  Google Scholar 

  139. Saubermann LJ, Deneau M, Falcone RA, et al. Hepatic issues and complications associated with inflammatory bowel disease: a clinical report from the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees. J Pediatr Gastroenterol Nutr. 2017;64:639–52.

    Article  PubMed  Google Scholar 

  140. Ricciuto A, Fish J, Carman N, et al. Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2018;16(7):1098–105.

    Article  PubMed  Google Scholar 

  141. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–6.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Sinakos E, Samuel S, Enders F, Loftus EV Jr, Sandborn WJ, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013;19:1004–9.

    Article  PubMed  Google Scholar 

  143. Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010;51:140–5.

    Article  PubMed  Google Scholar 

  144. Ricciuto A, Kamath BM, Griffiths AM. The IBD and PSC phenotypes of PSC-IBD. Curr Gastroenterol Rep. 2018;20(4):16. https://doi.org/10.1007/s11894-018-0620-2.

    Article  PubMed  Google Scholar 

  145. Shiau H, Ihekweazu FD, Amin M, et al. Unique inflammatory bowel disease phenotype of pediatric primary sclerosing cholangitis: a single-center study. J Pediatr Gastroenterol Nutr. 2017;65:404–9.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Deneau M, Jensen MK, Holmen J, et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013;58:1392–400.

    Article  PubMed  Google Scholar 

  147. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.

    Article  CAS  PubMed  Google Scholar 

  148. Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42:522–6.

    Article  CAS  PubMed  Google Scholar 

  149. Angulo P, Batts KP, Jorgensen RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:2333–7.

    Article  CAS  PubMed  Google Scholar 

  150. Cullen SN, Chapman RW. Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005;21:933–48.

    Article  CAS  PubMed  Google Scholar 

  151. Shimizu M, Iwasaki H, Mase S, Yachie A. Successful treatment of primary sclerosing cholangitis with a steroid and a probiotic. Case Rep Gastroenterol. 2012;6(2):249–53.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Stiehl A, Rudolph G, Kloters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36:151–6.

    Article  PubMed  Google Scholar 

  153. Alabraba E, Nightingale P, Gunson B, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15:330–40.

    Article  PubMed  Google Scholar 

  154. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, Part 1: Ambulatory care - an evidence-based guideline from ECCO and ESPGHAN. J Pediatr Gastroenterol Nutr. 2018; https://doi.org/10.1097/MPG.0000000000002035.

    Article  PubMed  Google Scholar 

  155. Mieli-Vergani G, Vergani D. Paediatric autoimmune liver disease. Arch Dis Child. 2013;98:1012–7.

    Article  PubMed  Google Scholar 

  156. Floreani A, Liberal R, Vergani D, et al. Autoimmune hepatitis: contrasts and comparisons in children and adults - a comprehensive review. J Autoimmun. 2013;46:7–16.

    Article  PubMed  Google Scholar 

  157. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213.

    Article  CAS  PubMed  Google Scholar 

  158. Mieli-Vergani G, Vergani D, Baumann U, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee position statement. J Pediatr Gastroenterol Nutr. 2018;66:345–60.

    Article  PubMed  Google Scholar 

  159. Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017. https://doi.org/10.1038/nrdp.2018.17.

    Article  PubMed  Google Scholar 

  160. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544–53.

    Article  CAS  PubMed  Google Scholar 

  161. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139(3):779–87.

    Article  PubMed  Google Scholar 

  162. Sridhar AR, Parasa S, Navaneethan U, et al. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis. 2011;5:287–94.

    Article  PubMed  Google Scholar 

  163. Fumery M, Xiaocang C, Dauchet L, et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2014;8(6):469–79.

    Article  PubMed  Google Scholar 

  164. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–63.

    Article  PubMed  Google Scholar 

  165. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99(1):97–101.

    Article  PubMed  Google Scholar 

  166. Yuhara H, Steinmaus C, Corley D, Koike J, Igarashi M, Suzuki T, Mine T. Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37(10):953–62.

    Article  CAS  PubMed  Google Scholar 

  167. DeLeve LD, Valla DC, Garcia-Tsao G, et al. Vascular disorders of the liver. Hepatology. 2009;49:1729–64.

    Article  CAS  PubMed  Google Scholar 

  168. Senzolo M, Riggio O, Primignani M, et al. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis. 2011;43(7):503–14.

    Article  PubMed  Google Scholar 

  169. Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835–48.

    Article  PubMed  Google Scholar 

  170. Papa A, Gerardi V, Marzo M, Felice C, Rapaccini GL, Gasbarrini A. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World J Gastroenterol. 2014;20(12):3173–9.

    Article  PubMed  PubMed Central  Google Scholar 

  171. Rogers BH, Clark LM, Kirsner JB. The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1400 patients. J Chronic Dis. 1971;24:743–73.

    Article  CAS  PubMed  Google Scholar 

  172. Betancourt SL, Palacio D, Jimenez CA, Martinez S, Marom EM. Thoracic manifestations of inflammatory bowel disease. AJR Am J Roentgenol. 2011;197:W452–6.

    Article  PubMed  Google Scholar 

  173. Abu-Hijleh M, Bassam SE. Pleuropericarditis in a patient with inflammatory bowel disease: a case presentation and review of the literature. Lung. 2010;188(6):505–10.

    Article  PubMed  Google Scholar 

  174. Ji X-Q, Wang L-X, Lu D-G. Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol. 2014;20(37):13501–11.

    Article  PubMed  PubMed Central  Google Scholar 

  175. Calder CJ, Lacy D, Raafat F, Weller PH, Booth IW. Crohn’s disease with pulmonary involvement in a 3 year old boy. Gut. 1993;34:1636–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest. 2007;131:524–32.

    Article  PubMed  Google Scholar 

  177. Marvisi M, Fornasari G. Is the lung a target organ in inflammatory bowel disease? Recenti Prog Med. 2001;92:774–7.

    CAS  PubMed  Google Scholar 

  178. MacDermott RP, Schloemann SR, Bertovich MJ, Nash GS, Peters M, Stenson WF. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 1989;96:442–8.

    Article  CAS  PubMed  Google Scholar 

  179. Higenbottam T, Cochrane GM, Clark TJ, Turner D, Millis R, Seymour W. Bronchial disease in ulcerative colitis. Thorax. 1980;35:581–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  180. Moles KW, Varghese G, Hayes JR. Pulmonary involvement in ulcerative colitis. Br J Dis Chest. 1988;82:79–83.

    Article  CAS  PubMed  Google Scholar 

  181. Garg K, Lynch DA, Newell JD. Inflammatory airways disease in ulcerative colitis: CT and high-resolution CT features. J Thorac Imaging. 1993;8:159–63.

    Article  CAS  PubMed  Google Scholar 

  182. Wilcox P, Miller R, Miller G, Heath J, Nelems B, Muller N, Ostrow D. Airway involvement in ulcerative colitis. Chest. 1987;92:18–22.

    Article  CAS  PubMed  Google Scholar 

  183. Karasalihoğlu A, Kutlu K, Yilmaz T. Laryngotracheal obstruction in ulcerative colitis (apropos of a case). Rev Laryngol Otol Rhinol (Bord). 1988;109:469–71.

    Google Scholar 

  184. Vasishta S, Wood JB, McGinty F. Ulcerative tracheobronchitis years after colectomy for ulcerative colitis. Chest. 1994;106:1279–81.

    Article  CAS  PubMed  Google Scholar 

  185. Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003;9:308–15.

    Article  PubMed  Google Scholar 

  186. Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest. 1999;116:1063–74.

    Article  CAS  PubMed  Google Scholar 

  187. Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore). 1993;72:151–83.

    Article  CAS  Google Scholar 

  188. Desai SJ, Gephardt GN, Stoller JK. Diffuse panbronchiolitis preceding ulcerative colitis. Chest. 1989;95:1342–4.

    Article  CAS  PubMed  Google Scholar 

  189. Ward H, Fisher KL, Waghray R, Wright JL, Card SE, Cockcroft DW. Constrictive bronchiolitis and ulcerative colitis. Can Respir J. 1999;6:197–200.

    Article  CAS  PubMed  Google Scholar 

  190. Veloso FT, Rodrigues H, Aguiar MM. Bronchiolitis obliterans in ulcerative colitis. J Clin Gastroenterol. 1994;19:339–41.

    Article  CAS  PubMed  Google Scholar 

  191. Bentur L, Lachter J, Koren I, Ben-Izhak O, Lavy A, Bentur Y, Rosenthal E. Severe pulmonary disease in association with Crohn’s disease in a 13-year-old girl. Pediatr Pulmonol. 2000;29:151–4.

    Article  CAS  PubMed  Google Scholar 

  192. Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J. 2000;15:41–8.

    Article  CAS  PubMed  Google Scholar 

  193. Papiris SA, Malagari K, Manali ED, Kolilekas L, Triantafillidou C, Baou K, Rontogianni D, Bouros D, Kagouridis K. Bronchiolitis: adopting a unifying definition and a comprehensive etiological classification. Expert Rev Respir Med. 2013;7:289–306.

    Article  CAS  PubMed  Google Scholar 

  194. Vandenplas O, Casel S, Delos M, Trigaux JP, Melange M, Marchand E. Granulomatous bronchiolitis associated with Crohn’s disease. Am J Respir Crit Care Med. 1998;158:1676–9.

    Article  CAS  PubMed  Google Scholar 

  195. Heatley RV, Thomas P, Prokipchuk EJ, Gauldie J, Sieniewicz DJ, Bienenstock J. Pulmonary function abnormalities in patients with inflammatory bowel disease. Q J Med. 1982;51:241–50.

    CAS  PubMed  Google Scholar 

  196. Haralambou G, Teirstein AS, Gil J, Present DH. Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. Mt Sinai J Med. 2001;68:384–8.

    CAS  PubMed  Google Scholar 

  197. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:104–15.

    Article  PubMed  Google Scholar 

  198. Carratú P, Dragonieri S, Nocerino MC, Trabucco SM, Lacedonia D, Parisi G, Resta O. A case of cryptogenic organizing pneumonia occurring in Crohn’s disease. Can Respir J. 2005;12:437–9.

    Article  PubMed  Google Scholar 

  199. Hardarson S, Labrecque DR, Mitros FA, Neil GA, Goeken JA. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis. Am J Clin Pathol. 1993;99:277–81.

    Article  CAS  PubMed  Google Scholar 

  200. Krishnan S, Banquet A, Newman L, Katta U, Patil A, Dozor AJ. Lung lesions in children with Crohn’s disease presenting as nonresolving pneumonias and response to infliximab therapy. Pediatrics. 2006;117:1440–3.

    Article  PubMed  Google Scholar 

  201. Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn’s disease. Can J Gastroenterol. 2004;18:687–90.

    Article  PubMed  Google Scholar 

  202. Patwardhan RV, Heilpern RJ, Brewster AC, Darrah JJ. Pleuropericarditis: an extraintestinal complication of inflammatory bowel disease. Report of three cases and review of literature. Arch Intern Med. 1983;143:94–6.

    Article  CAS  PubMed  Google Scholar 

  203. Orii S, Chiba T, Nakadate I, Fujiwara T, Ito N, Ishii M, Oana S, Chida T, Kudara N, Terui T, et al. Pleuropericarditis and disseminated intravascular coagulation in ulcerative colitis. J Clin Gastroenterol. 2001;32:251–4.

    Article  CAS  PubMed  Google Scholar 

  204. Abu-Hijleh M, Evans S, Aswad B. Pleuropericarditis in a patient with inflammatory bowel disease: a case presentation and review of the literature. Lung. 2010;188:505–10.

    Article  PubMed  Google Scholar 

  205. Smith PA, Crampton JR, Pritchard S, Li C. Pneumothorax as a presenting feature of granulomatous disease of the lung in a patient with Crohn’s disease. Eur J Gastroenterol Hepatol. 2009;21:237–40.

    Article  PubMed  Google Scholar 

  206. Desai D, Patil S, Udwadia Z, Maheshwari S, Abraham P, Joshi A. Pulmonary manifestations in inflammatory bowel disease: a prospective study. Indian J Gastroenterol. 2011;30:225–8.

    Article  PubMed  Google Scholar 

  207. Karmy-Jones R, Chagpar A, Vallieres E, Hamilton S. Colobronchial fistula due to Crohn’s disease. Ann Thorac Surg. 1995;60:446–8.

    Article  CAS  PubMed  Google Scholar 

  208. Domej W, Kullnig P, Petritsch W, Melisch B, Schaflinger E, Smolle-Jüttner FM, Schalk V, Ratschek M. Colobronchial fistula: a rare complication of Crohn’s colitis. Am Rev Respir Dis. 1990;142:1225–7.

    Article  CAS  PubMed  Google Scholar 

  209. Flueckiger F, Kullnig P, Melzer G, Posch E. Colobronchial and gastrocolic fistulas: rare complication of Crohn’s disease. Gastrointest Radiol. 1990;15:288–90.

    Article  CAS  PubMed  Google Scholar 

  210. Mera A, Sugimoto M, Fukuda K, Tanaka F, Imamura F, Matsuda M, Ando M, Shima K. Crohn’s disease associated with colo-bronchial fistula. Intern Med. 1996;35:957–60.

    Article  CAS  PubMed  Google Scholar 

  211. Gumbo T, Rice TW, Mawhorter S. Recurrent pneumonia from an ileobronchial fistula complicating Crohn’s disease. J Clin Gastroenterol. 2001;32:365–7.

    Article  CAS  PubMed  Google Scholar 

  212. Singh D, Cole JC, Cali RL, Finical EJ, Proctor DD. Colobronchial fistula: an unusual complication of Crohn’s disease. Am J Gastroenterol. 1994;89:2250–2.

    CAS  PubMed  Google Scholar 

  213. Barisiae G, Krivokapiae Z, Adziae T, Pavloviae A, Popoviae M, Gojniae M. Fecopneumothorax and colopleural fistula - uncommon complications of Crohn’s disease. BMC Gastroenterol. 2006;6:17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Pasquis P, Colin R, Denis P, Baptiste P, Galmiche JP, Hecketsweiler P. Transient pulmonary impairment during attacks of Crohn’s disease. Respiration. 1981;41:56–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

    Skirmante Rusoniene & Vaidotas Urbonas

  2. Children Hospital, Affiliate of Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania

    Skirmante Rusoniene & Vaidotas Urbonas

  3. Department of Allergology, Rheumatology and Clinical Immunology, Children’s Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia

    Tadej Avcin

  4. Department of Pediatrics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

    Tadej Avcin

Authors
  1. Skirmante Rusoniene
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vaidotas Urbonas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadej Avcin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadej Avcin .

Editor information

Editors and Affiliations

  1. Department of Clinical Sciences and Community Health, University of Milano, Milano, Italy

    Rolando Cimaz

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rusoniene, S., Urbonas, V., Avcin, T. (2020). Extraintestinal Manifestations of Inflammatory Bowel Disease. In: Cimaz, R. (eds) Periodic and Non-Periodic Fevers. Rare Diseases of the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-030-19055-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-19055-2_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-19054-5

  • Online ISBN: 978-3-030-19055-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation